Short answer
Regeneron Pharmaceuticals (REGN) filed its Q2 2026 10-Q quarterly report on Jul 30, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $4.3B (up 16.7% year over year) with net income of $1.3B.
Q2 2026 key financials · XBRL
- Revenue
- $4.3B
- +16.7% YoY · +19.0% QoQ
- Net income
- $1.3B
- −6.8% YoY · +78.3% QoQ
- Operating margin
- 30.1%
- EPS (diluted)
- $12.20
- −4.3% YoY · +80.7% QoQ
Source: XBRL data from the Regeneron Pharmaceuticals (REGN) Q2 2026 10-Q on SEC EDGAR. USD.
Regeneron Pharmaceuticals Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $4,290.7M, up 16.7% YoY from $3,675.6M
- Net income $1,296.9M vs $1,391.6M YoY, diluted EPS $12.23 vs $12.81
- Dupixent sales $5,998.2M, up 38%; EYLEA HD sales $962.6M, up 52%
- EYLEA sales $712.4M, down 52%; combined EYLEA HD and EYLEA sales $1,675.0M, down 21%
- Near-term milestones include FDA decisions for EYLEA HD pre-filled syringe and gMG NDA in November 2026
Risk Factors
- EYLEA U.S. sales decline 41% for six months, reflecting biosimilar competition after exclusivity expired in May 2024
- Dupixent collaboration revenue 48% of total revenue, increasing dependence on Sanofi commercialization
- Pending EYLEA intellectual-property proceedings could affect commercialization and product revenue
- Government healthcare pricing measures could reduce reimbursement, coverage, and product pricing
- EYLEA HD and EYLEA U.S. sales represented 25% of total revenue, creating product concentration risk
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Regeneron Pharmaceuticals quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.